Conversation has moved to delivery: the call's center of gravity is how and when real business converts, not whether it
The model's full reasoning — Q2 2023 call → NOThe question asks whether the center of gravity of the discussion has moved past the question of whether demand exists, and onto the practical mechanics of converting real business into delivered results. Let me analyze the transcript: 1. The business being discussed - KEDRAB sales to Kedrion for U.S. distribution, the IgG product portfolio (CYTOGAM, HEPAGAMB, VARIZIG, WINRHO), the Israeli distribution business, and the InnovAATe Phase III trial. 2. Key elements: - KEDRAB: "significant increase in demand for the product in the U.S." - actual sales happening, Kedrion extended distribution agreement through 2026. Revenue from KEDRAB was $16 million in 2022, and there's been significant increase in first half 2023. - The IgG products: FDA approval to manufacture CYTOGAM at Israeli facility, Health Canada approval obtained, expect to initiate sales of product manufactured in Israeli facility early Q4 2023. - InnovAATe trial: enrollment ramping, 62 patients enrolled through end of July (~30% of required enrollment). EMA positive scientific advice received. - The $60 million financing from FIMI - pending shareholder approval. 3. Analysts' questions: - Annabel Samimy asked about InnovAATe program - the EMA endpoint confirmation, what sticking points remain with FDA, enrollment learnings, and about the $60 million financing and BD priorities. 4. Management's responses: - Discussed the EMA feedback, FDA discussions planned, enrollment dynamics in Europe - Discussed BD focus areas and preclinical programs - Discussed KEDRAB market dynamics driving increased demand Now, is the business "already real"? The KEDRAB sales are real and growing. The IgG products are being sold. The InnovAATe trial is enrolling. But the InnovAATe trial is still in Phase III - it's prospective, not yet generating revenue. The $60 million financing is pending approval. Is the dialogue dwelling on conversion mechanics? The analysts' questions were about: - InnovAATe program design and FDA discussions - Enrollment learnings - BD priorities and use of proceeds Management's answers were about: - Study design harmonization between EMA and FDA - Enrollment focus in Europe - BD focus areas - KEDRAB market dynamics The KEDRAB discussion is about market share expansion and demand dynamics - this is more about winning/stimulating demand than converting existing committed business.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ERO | Ero Copper Corp. | Q1 2024 | 2024-05-10 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| GOLD | Barrick Gold Corporation | Q3 2023 | 2023-11-02 | C |
| CMG | Chipotle Mexican Grill, Inc. | Q3 2023 | 2023-10-27 | B+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SU | Suncor Energy Inc. | Q1 2023 | 2023-05-09 | C+ |
| ULCC | Frontier Group Holdings, Inc. | Q1 2023 | 2023-05-07 | C+ |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| HY | Hyster-Yale Materials Handling, Inc. | Q3 2021 | 2021-11-06 | D |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| FFWM | First Foundation Inc. | Q3 2021 | 2021-10-26 | B |
| EGY | VAALCO Energy, Inc. | Q2 2021 | 2021-08-12 | B |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| JBT | John Bean Technologies Corporation | Q2 2018 | 2018-07-26 | B |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| EPAM | EPAM Systems, Inc. | Q4 2017 | 2018-02-16 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| ABM | ABM Industries Incorporated | Q2 2017 | 2017-06-08 | B |
| FIX | Comfort Systems USA, Inc. | Q1 2017 | 2017-04-30 | A |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
GOLD · Q3 2023 → YESThe question is: Has the center of gravity of the discussion moved past whether demand exists, onto the practical mechanics of converting already real business into delivered results? YES The transcript shows the center of gravity has shifted to execution mechanics for already-committed operations and growth projects. Management details current production (up QoQ at NGM, Loulo-Gounkoto, Kibali), specific ramp-up challenges and fixes at Pueblo Viejo (gearbox failures, conveyor issues, temporary 70-75% throughput solutions, new assemblages arriving end-2023), tailings permitting, and phased construction at RekoDiq/Lumwana (2025 start, 2028/2026 first production). Analysts press on Q4 production, 2024 profiles (PV >800koz despite delays), recovery rates 70% to design, capital sequencing ($2.5B 2024, peaks 2025-26), and conversion timing (downtimes, relocations, training).
LBTYK · Q1 2016 → YESThe question is: Has the center of gravity of the discussion moved past whether demand exists, onto the practical mechanics of converting already real business into delivered results? YES The call as a whole satisfies both conditions. Management repeatedly frames the business as already real—existing customer bases, price increases already implemented across two-thirds of the footprint, 210,000 new-build homes added in Q1, 330,000 premises released under Project Lightning, 100,000 postpaid mobile subs added organically, BASE integration underway, and the Cable & Wireless transaction closing next week.
DXCM · Q4 2023 → YESThe question is: has the CENTER OF GRAVITY of the discussion visibly moved PAST the question of whether demand for the company's offering exists, and ONTO the practical mechanics of converting busines...